General drug maker Amniotic Clock Mixes Q4 revenue, plans to expand in high-growth areas such as weight loss products, biosimilars – Amneal Pharmaceuticals (NASDAQ:AMRX)

On Friday, Amneal Pharmaceuticals Inc. AMRX The fourth-quarter adjusted earnings per share was reported at 12 cents, down from 14 cents a year ago, missing a consensus of $0.15.

The company reported sales of $733.2 million, up 18% year-on-year, surpassing the $707.6 million consensus.

Due to new product launches, biosimilars and multiple complex products, 21% increase due to affordable drugs (formerly) revenue growth, Avkare revenue growth 14% and 16% increase due to new product launches, and featured revenue growth, which is 16% driven by key brand products including Crexont.

Also Read: Generic drug maker Amneal Pharmaceuticals sits ahead of peers, analysts upgrade inventory

Its net loss was $31 million, while its net loss was $99 million. Adjusted EBITDA for the fourth quarter of 2024 was $155 million, up 9% from the fourth quarter of 2023, mainly due to strong revenue growth, partly due to higher spending in R&D and business plans to drive future growth.

guide: Amneal expects $3 billion in revenue and $3.1 billion in 2025, with adjusted earnings per share of $0.65 to $0.70, while consensus is $2.9 billion and $0.71, respectively.

“In 2025 and beyond, we are entering a new phase of growth by further expanding in high-growth areas such as Specialty, Biosimilars, and GLP-1 therapies. As a growing and diversified biopharmaceutical company, Amneal is well positioned to deliver substantial value creation for all our stakeholders,” said Chirag and Chitu Patel, Co-Chief Executive Officers.

The company expects adjusted EBITDA of $650 million, $675 million in 2025, operating cash flow of $255 million to $225 million and capital expenditure of about $100 million.

Price action: At the time of writing, AMRX stock rose 1.43% on Friday, at $8.50 during the pre-sale period.

Read the next article: